Related Experiment Video
Updated: May 7, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Integrated genomic analysis of breast cancers
L Addou-Klouche1, J Adélaïde, S Cornen
1Marseille Cancer Research Center, Department of Molecular Oncology, UMR891 Inserm; Institut Paoli-Calmettes, Marseille, France ; Biotoxicology Laboratory, Djillali Liabes University, Sidi-Bel-Abbès, Algeria.
Balkan Journal of Medical Genetics : BJMG
|September 21, 2013
Summary
Breast cancer's current classifications miss molecular diversity, impacting treatment accuracy. Identifying new molecular subtypes and targets is crucial for personalized breast cancer therapy and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer exhibits significant clinical heterogeneity not captured by current classification systems.
- Existing diagnostic and prognostic tools inadequately address molecular diversity, leading to suboptimal treatment strategies and variable patient outcomes.
- Current breast cancer treatments are effective in only 70-75% of cases, highlighting the need for improved patient stratification.
Purpose of the Study:
- To address the limitations of current breast cancer classifications by exploring molecular heterogeneity.
- To identify novel molecularly distinct subgroups, biomarkers, and therapeutic targets for breast cancer.
- To improve the accuracy of diagnostic, prognostic, and predictive tests for personalized treatment selection.
Main Methods:
- Comprehensive molecular characterization of breast tumors, including genetic and epigenetic alterations and gene expression profiling.
- Integration of large-scale molecular data to identify new biologically and clinically relevant tumor classes.
- Functional validation of identified molecular alterations to discover new therapeutic targets.
Main Results:
- Current classifications fail to reflect the full clinical heterogeneity of breast cancer.
- Molecularly distinct subgroups exist within current clinical classes, explaining varied patient outcomes.
- Discovery of new molecular targets and pathways is essential for advancing breast cancer therapy.
Conclusions:
- Integrated molecular characterization is key to uncovering new breast cancer subtypes and improving patient stratification.
- Identification of novel molecular markers and therapeutic targets will enhance personalized medicine approaches in breast cancer treatment.
- Further research into the genetic and epigenetic events driving breast cancer is needed to define tumorigenesis stages and develop more effective therapies.
